Strontium-89 for bone metastases from prostate cancer: an update.
- Author:
Wei-wei ZHAO
1
;
Peng XIE
;
Hou-fu DENG
Author Information
1. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Publication Type:Journal Article
- MeSH:
Bone Neoplasms;
radiotherapy;
secondary;
Humans;
Male;
Neoplasm Metastasis;
Prostatic Neoplasms;
pathology;
radiotherapy;
Strontium Radioisotopes;
therapeutic use
- From:
National Journal of Andrology
2010;16(3):269-272
- CountryChina
- Language:Chinese
-
Abstract:
Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 +/- 4 to 231 +/- 56 cGy/MBq, 2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer, with analgesic effectiveness in 80%.
